BioGene Therapeutics
Austin, US · Founded 2024 · Texas corporation
Find your way into BioGene Therapeutics
Sign up to see every warm intro you have to BioGene Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BioGene Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Board
DS
DEEPAK SAMPATHBoard director
PL
PATROSKI LAWSONBoard director
SG
STEVE GLOVERBoard director
RP
RAJ PRUTHIBoard director
DT
DAVID TYRONNE HOWTONBoard director
Reported raises · per SEC filings
Form D private placements$11.1M disclosed across 5 rounds · 2025–2026
▶$3MraisedAug 2026 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedAug 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STEPHEN VAN DEVENTERExecutive Officer, Director
- DEEPAK SAMPATHDirector
- PATROSKI LAWSONDirector
- STEVE GLOVERDirector
- RAJ PRUTHIDirector
- DAVID TYRONNE HOWTONDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Jun 2026
- Incorporated
- Corporation, Texas, 2024
- Federal exemptions
- 06b
▶$250KraisedAug 2026 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedAug 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STEPHEN VAN DEVENTERExecutive Officer, Director
- DEEPAK SAMPATHDirector
- PATROSKI LAWSONDirector
- STEVE GLOVERDirector
- RAJ PRUTHIDirector
- DAVID TYRONNE HOWTONDirector
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Aug 2025
- Incorporated
- Corporation, Texas, 2024
- Federal exemptions
- 06b
▶$250KraisedAug 2026 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedAug 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STEPHEN VAN DEVENTERExecutive Officer, Director
- DEEPAK SAMPATHDirector
- PATROSKI LAWSONDirector
- STEVE GLOVERDirector
- RAJ PRUTHIDirector
- DAVID TYRONNE HOWTONDirector
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Aug 2025
- Incorporated
- Corporation, Texas, 2024
- Federal exemptions
- 06b
▶$3MraisedAug 2026 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedAug 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STEPHEN VAN DEVENTERExecutive Officer, Director
- DEEPAK SAMPATHDirector
- PATROSKI LAWSONDirector
- STEVE GLOVERDirector
- RAJ PRUTHIDirector
- DAVID TYRONNE HOWTONDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Mar 2026
- Incorporated
- Corporation, Texas, 2024
- Federal exemptions
- 06b
▶$4.5MraisedJul 2026 · 6 investors · BiotechnologyRule 506(b)
▶$4.5MraisedJul 2026 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- STEPHEN VAN DEVENTERExecutive Officer, Director
- DEEPAK SAMPATHDirector
- PATROSKI LAWSONDirector
- STEVE GLOVERDirector
- RAJ PRUTHIDirector
- DAVID TYRONNE HOWTONDirector
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- First sale
- Apr 2025
- Incorporated
- Corporation, Texas, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has BioGene Therapeutics raised?
- BioGene Therapeutics has disclosed $11.1M raised across 5 rounds.
- Where is BioGene Therapeutics headquartered?
- BioGene Therapeutics is headquartered in Austin, US.
